{"id":30585,"date":"2025-08-21T12:48:35","date_gmt":"2025-08-21T12:48:35","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/brii-biosciences-provides-corporate-updates-and-reports-2025-interim-financial-results\/"},"modified":"2025-08-21T12:48:35","modified_gmt":"2025-08-21T12:48:35","slug":"brii-biosciences-provides-corporate-updates-and-reports-2025-interim-financial-results","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=30585","title":{"rendered":"Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Multiple Ongoing Phase 2b<\/span> Studies Advancing HBV Functional Cure Strategy<\/i><\/p>\n

Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic soralimixin<\/i><\/p>\n

Strong Cash Position to Pursue New Discovery Opportunities and Partnership Strategy<\/i><\/p>\n

Conference Calls Scheduled:\u00a0
<\/i>English Session: <\/i>August 21<\/span> at 9:00 p.m.<\/span> HKT \/ 9:00 a.m. ET\u00a0
<\/i>Chinese Session: August 22<\/span> at 9:00 a.m.<\/span> HKT \/ August 21<\/span> at 9:00 p.m. ET<\/span><\/i><\/p>\n

DURHAM, N.C.<\/span>, and BEIJING<\/span><\/span>, Aug. 21, 2025<\/span><\/span> \/PRNewswire\/ — Brii Biosciences Limited<\/a>\u00a0(“Brii Bio<\/span>,” or the “Company,” stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical need, today provided a corporate update and reported its financial results for the six-month period ended June 30, 2025<\/span>.<\/p>\n

\n<\/div>\n

In the first half of 2025, Brii Bio<\/span> rapidly advanced its core hepatitis B virus (HBV) functional cure program through multiple confirmatory Phase 2b<\/span> trials, including ENRICH and ENHANCE studies, seeking combination regimens with higher HBV functional cure rates. Encouraged by promising data from Cohort 4 of the ENSURE study, presented at both the Asian Pacific Association for the Study of the Liver (APASL) and the European Association for the Study of the Liver (EASL) Congress 2025 supporting the potential of its patient enrichment strategy through BRII-179 induced anti-HBs response, the Company initiated a new cohort in an amended protocol within the ENHANCE study. This amendment evaluates a new triple regimen cohort with BRII-179 and elebsiran combination treatment followed by an added short-course pegylated interferon alpha (PEG-IFN\u03b1) treatment. This new cohort was fully enrolled in July 2025<\/span>. Beyond its HBV pipeline, Brii Bio<\/span> entered into a strategic license collaboration with Joincare Pharmaceutical Group Industry Co., Ltd (“Joincare\u00a0Group”) for the development of soralimixin (BRII-693) in the Greater China<\/span> region. The Company has expanded its new discovery efforts to further broaden its portfolio and will continue to pursue partnership to extend the cash runway. \u00a0<\/p>\n

With effective cost control measures in place, Brii Bio<\/span> remains well-capitalized, maintaining a cash position of US$289.9 million<\/span>, which is sufficient to support its late-stage development plans for its core HBV functional cure program and early discovery initiatives.<\/p>\n

“We made significant strides in our HBV cure program during the first half of 2025, highlighted by encouraging\u00a0data from Cohort 4 of the ENSURE study and the rapid advancement of ENRICH and ENHANCE studies.” said Dr. Zhi Hong<\/span>, Chairman and Chief Executive Officer of Brii Bio<\/span>, “These achievements reflect Brii’s experience and commitment to discovering innovative curative treatments for patients with chronic HBV infection. Meanwhile, the out-licensing of soralimixin in Greater China<\/span> and our continued investment in early-stage discovery programs reinforce our strategy of combining internal innovation with strategic external collaborations to drive sustainable growth.”<\/p>\n

Corporate and Clinical Updates<\/b><\/p>\n

HBV Program<\/b><\/p>\n

Brii Bio\u00a0continues to advance its HBV pipeline with a strong focus on achieving higher\u00a0rates of HBV functional cure through novel combination regimens. The Company is progressing multiple ongoing Phase 2b<\/span> combination studies (ENSURE, ENRICH and ENHANCE) with its differentiated HBV candidates, including elebsiran, an HBV-targeting siRNA, and\u00a0BRII-179, a recombinant protein-based HBV immunotherapeutic.\u00a0<\/p>\n